AC Immune anticipates that its total cash burn will be in the range of CHF 65 to CHF 75 million for the full year 2023. The Company defines cash burn as operating expenditures adjusted to include capital expenditures and offset by significant non-cash items
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACIU:
- AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
- AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
- AC Immune awarded new grants from MJFF, Target ALS
- AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
- AC Immune to Present at the SVB Securities Global Biopharma Conference